

**(12) STANDARD PATENT  
(19) AUSTRALIAN PATENT OFFICE**

**(11) Application No. AU 2013240003 B2**

(54) Title  
**Purification of cystathionine beta-synthase**

(51) International Patent Classification(s)  
**C12N 9/88** (2006.01)

(21) Application No: **2013240003** (22) Date of Filing: **2013.03.25**

(87) WIPO No: **WO13/148580**

(30) Priority Data

(31) Number	(32) Date	(33) Country
<b>61/615,629</b>	<b>2012.03.26</b>	<b>US</b>
<b>13/830,494</b>	<b>2013.03.14</b>	<b>US</b>

(43) Publication Date: **2013.10.03**

(44) Accepted Journal Date: **2018.04.19**

(71) Applicant(s)  
**The Regents of the University of Colorado**

(72) Inventor(s)  
**Carrillo, Richard G.;Kraus, Jan P.;Majtan, Tomas;Naveh, David**

(74) Agent / Attorney  
**Wrays, L7 863 Hay St, Perth, WA, 6000, AU**

(56) Related Art  
**BELEW M S ET AL, PROTEIN EXPRESSION AND PURIFICATION, 2009, vol. 64, pages 139 - 145 EP 1878739 A1**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



(10) International Publication Number

WO 2013/148580 A1

(43) International Publication Date  
3 October 2013 (03.10.2013)

(51) International Patent Classification:  
*C12N 9/88* (2006.01)

(21) International Application Number:  
PCT/US2013/033716

(22) International Filing Date:  
25 March 2013 (25.03.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
61/615,629 26 March 2012 (26.03.2012) US  
13/830,494 14 March 2013 (14.03.2013) US

(71) Applicant (for all designated States except US): **THE REGENTS OF THE UNIVERSITY OF COLORADO** [US/US]; 1800 Grant Street, 8th Floor, Denver, CO 80203 (US).

(72) Inventors; and

(71) Applicants (for US only): **CARRILLO, Richard, G.** [US/US]; 725 45th Street, Oakland, CA 94609 (US). **KRAUS, Jan, P.** [US/US]; 5000 Lakeshore Drive, Littleton, CO 80123 (US). **MAJTAN, Thomas** [US/US]; 100 Idalia Court, Apt. #302, Aurora, CO 80011 (US). **NAVEH, David** [US/US]; 119 Monte Avenue, Piedmont, CA 94611 (US).

(74) Agent: **BOSMAN, Joshua, D.**; McDonnell Boehnen Hulbert & Berghoff LLP, 300 South Wacker Drive, Suite 3100, Chicago, IL 60606 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))



WO 2013/148580 A1

(54) Title: PURIFICATION OF CYSTATHIONINE BETA-SYNTHASE

(57) Abstract: This invention provides chromatographic methods for the purification of a cystathionine  $\beta$ -Synthase (CBS) protein, particularly truncated variants thereof and compositions and pharmaceutical compositions prepared therefrom.

## PURIFICATION OF CYSTATHIONINE BETA-SYNTHASE

### Cross-Reference to Related Applications

This application claims the benefit of U.S. Provisional Application No. 61/615,629, filed 5 March 26, 2012, and U.S. Application No. 13/830,494, filed March 14, 2013, the disclosure of each of which is incorporated by reference.

### Field of the Invention

10 The present invention generally relates to methods for purification of Cystathionine  $\beta$ -Synthase (CBS), particularly truncated variants thereof. The present invention also relates to compositions of substantially pure CBS produced through said methods of purification.

### Background of the Invention

Cystathionine  $\beta$ -synthase (CBS) plays an essential role in homocysteine (Hcy) metabolism in eukaryotes (Mudd *et al.*, 2001, in *The Metabolic and Molecular Bases of Inherited Disease*, 8 Ed., pp. 2007-2056, McGraw-Hill, New York). The CBS enzyme catalyzes a pyridoxal 5'-phosphate (PLP; Vitamin B<sub>6</sub>)-dependent condensation of serine and homocysteine 20 to form cystathionine, which is then used to produce cysteine by another PLP-dependent enzyme, cystathionine  $\gamma$ -lyase. In mammalian cells that possess the transsulfuration pathway, CBS occupies a key regulatory position between the remethylation of Hcy to methionine or its alternative use in the biosynthesis of cysteine. The relative flux between these two competing pathways is roughly equal and is controlled by intracellular S-adenosylmethionine (AdoMet) 25 concentrations (Finkelstein and Martin, 1984, *J. Biol. Chem.* 259:9508-13). AdoMet activates the mammalian CBS enzyme by as much as 5-fold with an apparent dissociation constant of 15 $\mu$ M

(Finkelstein *et al.*, 1975, *Biochem. Biophys. Res. Commun.* 66: 81-87; Roper *et al.*, 1992, *Arch. Biochem. Biophys.* 298: 514-521; Kozich *et al.*, 1992, *Hum. Mutation* 1: 113-123).

The C-terminal regulatory domain of human CBS consists of ~140 amino acid residues (Kery *et al.*, 1998, *Arch. Biochem. Biophys.* 355: 222-232). This region is required for 5 tetramerization of the human enzyme and AdoMet activation (Kery *et al.*, 1998, *id.*). The C-terminal regulatory region also encompasses the previously defined "CBS domains" (Bateman, 1997, *Trends Biochem. Sci.* 22: 12-13). These hydrophobic sequences (CBS 1 and CBS 2), spanning amino acid residues 416-468 and 486-543 of SEQ ID NO: 1, respectively, are conserved in a wide range of otherwise unrelated proteins. Their function remains unknown, 10 although the sharp transition of thermally induced CBS activation and the observation that mutations in this domain can constitutively activate the enzyme indicates that they play a role in the autoinhibitory function of the C-terminal region (Janosik *et al.*, 2001, *Biochemistry* 40: 10625-33; Shan *et al.*, 2001, *Hum. Mol. Genet.* 10: 635-643; Miles and Kraus, 2004, *J. Biol. Chem.* 279: 29871-4). Two well-conserved CBS domains are also present in the C-terminal 15 region of the yeast CBS, which is of approximately the same length as the human enzyme.

In healthy normal individuals, CBS-mediated conversion of Hcy to cystathionine is the rate-limiting intermediate step of methionine (Met) metabolism to cysteine (Cys). Vitamin B<sub>6</sub> is an essential coenzyme for this process. In patients with certain genetic mutations in the CBS enzyme, the conversion of Hcy to cystathionine is slowed or absent, resulting in elevations in the 20 serum concentrations of the enzymatic substrate (Hcy) and a corresponding decrease in the serum concentrations of the enzymatic product (cystathionine). The clinical condition of an elevated serum level of Hcy, and its concomitant excretion into the urine, is collectively known as homocystinuria.

Deficiency of CBS is the most common cause of inherited homocystinuria, a serious life-threatening disease that results in severely elevated homocysteine levels in plasma, tissues and urine. Estimates on the prevalence of homocystinuria vary widely. Ascertainment by newborn screening and clinical ascertainment have indicated a prevalence ranging from 1:200,000 to 5 1:335,000 (Mudd *et al.*, 1995, *The Metabolic and Molecular Basis of Inherited Diseases*, McGraw-Hill: New York, p. 1279). The primary health problems associated with CBS-deficient homocystinuria (CBS-DH) include: cardiovascular disease with a predisposition to thrombosis, resulting in a high rate of mortality in untreated and partially treated patients; connective tissue problems affecting the ocular system with progressive myopia and lens dislocation; connective 10 tissue problems affecting the skeleton characterized by marfanoid habitus, osteoporosis, and scoliosis; and central nervous system problems, including mental retardation and seizures. Symptoms include dislocated optic lenses, skeletal disorders, mental retardation and premature arteriosclerosis and thrombosis (Mudd *et al.*, 2001, *id.*). Homozygous CBS deficiency is associated with a multitude of clinical symptoms, including mental retardation, osteoporosis, 15 kyphoscoliosis, stroke, myocardial infarction, ectopia lentis, and pulmonary embolism. Cardiovascular complications of the disease, in particular arterial and venous thrombosis, are the principal contributors to early mortality.

The pathophysiology of CBS deficiency is undoubtedly complex, but there is a consensus that the fundamental instigator of end-organ injury is an extreme elevation of serum Hcy, a 20 substrate of CBS that builds-up in tissues and blood due to the absence of its CBS-catalyzed condensation with L-serine to form cystathione. The toxicity of profound elevations in blood and tissue concentrations of Hcy may ensue from the molecular reactivity and biological effects of Hcy *per se* or from its metabolites (*e.g.* Hcy-thiolactone) that affect a number of biological

processes (Jakubowski *et al.*, 2008, *FASEB J* 22: 4071-6). Abnormalities in chronic platelet aggregation, changes in vascular parameters, and endothelial dysfunction have all been described in patients with homocystinuria.

Currently, three treatment options exist for the treatment of CBSDH:

- 5 1) Increase of residual activity of CBS activity using pharmacologic doses of Vitamin B<sub>6</sub> in Vitamin B<sub>6</sub>-responsive patients
- 2) Lowering of serum Hcy by a diet with a strict restriction of the intake of Met; and
- 3) Detoxification by betaine-mediated conversion of Hcy into Met, thus lowering serum Hcy concentration.

10 Each of these three therapies is aimed at lowering serum Hcy concentration. The standard treatment for individuals affected with Vitamin B<sub>6</sub> non-responsive CBSDH consists of a Met-restricted diet supplemented with a metabolic formula and Cys in the form of cysteine (which has become a conditionally essential amino acid in this condition). Intake of meat, dairy products, and other food high in natural protein is prohibited. Daily consumption of a poorly 15 palatable, synthetic metabolic formula containing amino acids and micronutrients is required to prevent secondary malnutrition. Supplementation with betaine (trade name: Cystadane<sup>TM</sup>, synonym: trimethylglycine) is also standard therapy, wherein betaine serves as a methyl donor for the remethylation of Hcy to Met catalyzed by betaine-homocysteine methyltransferase in the liver (Wilcken *et al.*, 1983, *N. Engl. J. Med.* 309: 448-53). Dietary compliance generally has 20 been poor, even in those medical centers where optimal care and resources are provided, and this non-compliance has major implications on the development of life-threatening complications of homocystinuria.

To enable patients with homocystinuria enjoy a far less restrictive diet (*e.g.* daily intake

limited to 2 g protein per kg, which is easily attainable), and have a significantly decreased Hcy plasma level leading in the long-term to clinical improvement, a strategy for increasing enzyme activity provides potential for treatment as set forth in co-pending U.S. provisional patent application Serial No. 61/758,138 . The most effective therapeutic strategy is to increase enzyme 5 activity, as is evident when Vitamin B<sub>6</sub>-responsive homocystinuria patients are given pyridoxone. However, this strategy is not possible for Vitamin B<sub>6</sub> non-responsive patients due to the nature of the mutations. Enzyme replacement therapy (ERT) as a way to increase enzyme activity in these patients requires exogenous enzyme, which is not present in the art and thus raises a need in the art for improved reagents and methods for producing CBS in greater yields of 10 sufficiently purified enzyme for therapeutic administration.

Kraus and colleagues have developed expression systems and fermentation conditions for generating active recombinant human CBS and variants thereof (US patents No. 5,635,375, 5,523,225 and 7,485,307, incorporated by reference herein in their entireties for any purpose). These proteins were purified by processes relevant for academic purposes, including use of 15 protein leads on the proteins which are not considered useful for preparation of pharmaceuticals.

In order to employ methods of increasing CBS enzyme activity, an efficient method of CBS enzyme purification is required. Existing methods of purification for recombinant CBS protein rely on affinity tags to facilitate purification that does not provide the desired purity and efficiency. Therefore to more efficiently obtain the necessary levels of CBS required for 20 therapeutic use there is a need for improved downstream purification of CBS protein produced in microbial cells.

### **Summary of the Invention**

This invention provides methods for purifying cystathionine  $\beta$ -Synthase (CBS), wherein said CBS protein is a naturally occurring truncated variant, or a chemically cleaved or genetically engineered truncate thereof, and particularly truncated CBS produced in recombinant cells. In particular embodiments, the method comprises the steps of: (a) providing a CBS-  
5 containing solution in the presence of at least one impurity; and (b) performing chromatographic separation of said CBS-containing solution using a metal affinity chromatography (IMAC) resin. In additional particular embodiments, the method comprises the steps of: (a) providing a CBS-  
containing solution in the presence of at least one impurity; and (b) performing chromatographic separation of said CBS-containing solution using an ion exchange chromatography column and a  
10 metal affinity chromatography (IMAC) resin.

In certain embodiments the method further comprises performance of additional chromatographic steps (known in the art as “polishing” steps). In particular embodiments, the methods of the invention include the step of performing chromatographic separation using a Hydrophobic Interaction Chromatography (HIC) column. In other embodiments the method  
15 further comprises the step of performing chromatographic separation using a ceramic hydroxyapatite resin.

In certain embodiments the ion exchange column is an anion exchanger, preferably a weak anion exchanger. In particular embodiments the anion exchanger is a DEAE-Sepharose FF column. In further embodiments the IMAC resin is charged with a divalent ion. In yet further  
20 embodiments the divalent metal ion is nickel, copper, cobalt or zinc. In more specific embodiments the divalent metal ion is zinc.

In certain other embodiments the method further comprises eluting CBS from the IMAC resin with an elution buffer comprising imidazole. In certain embodiments the CBS-containing

solution is a clarified CBS solution, wherein cell debris and other particulate matter is removed from a suspension comprising CBS including but not limited to supernatant after centrifugation or filtrate after filtration. In yet other embodiments the CBS-containing solution is obtained by homogenizing cells expressing a recombinant construct comprising a nucleic acid sequence 5 encoding CBS. In certain embodiments the CBS nucleic acid sequence comprises SEQ ID NO. 1 and encodes a protein have the amino acid sequence identified as SEQ ID NO: 2. In other embodiments the nucleic acid sequence is truncated. In yet other embodiments the truncated CBS nucleic acid sequence has been truncated to an ending position of one of amino acid residues from 382-532, 382-550 or 543-550 of SEQ ID NO:2

10           In other certain embodiments the recombinant cells are microbial cells, particularly bacterial cells. In particular embodiments, the bacterial cells are *E. coli* cells, particularly recombinant *E. coli* cells that produce a mammalian, preferably human, CBS protein. In certain particular embodiments, said human CBS protein has an amino acid sequence as set forth in SEQ ID NO:3 or a truncated CBS nucleic acid sequence that has been truncated to an ending position 15 of one of amino acid residues from 382-532 or 543-550 of SEQ ID NO:2. In other particular embodiments, the truncated CBS nucleic acid sequence is optimized for expression in *E. coli*, identified by SEQ ID NO: 4.

20           In another aspect, a substantially purified CBS solution is provided using a method comprising the steps of: a) providing a CBS-containing solution in the presence of at least one impurity, wherein said CBS protein is a naturally occurring truncated variant, or a chemically cleaved or genetically engineered truncate thereof, and particularly truncated; and (b) performing chromatographic separation of said CBS-containing solution using a metal affinity chromatography (IMAC) resin. In additional particular embodiments, a substantially purified

CBS solution is provided using a method comprising the steps of: (a) providing a CBS-containing solution in the presence of at least one impurity; and (b) performing chromatographic separation of said CBS-containing solution using an ion exchange chromatography column and a metal affinity chromatography (IMAC) resin.

5 In certain embodiments of the invention the substantially purified CBS solution is formulated in a pharmaceutically acceptable carrier.

In another aspect, the invention provides methods for producing an enriched CBS solution, the method comprising of: (a) providing a CBS-containing solution in the presence of at least one impurity, wherein said CBS protein is a naturally occurring truncated variant, or a 10 chemically cleaved or genetically engineered truncate thereof, and particularly truncated; and (b) performing chromatographic separation of said CBS-containing solution using an immobilized metal affinity chromatography (IMAC) resin charged with a divalent metal ion.

In another aspect, an enriched CBS solution is provided using a method comprising the steps of: a) providing a CBS-containing solution in the presence of at least one impurity, wherein 15 said CBS protein is a naturally occurring truncated variant, or a chemically cleaved or genetically engineered truncate thereof, and particularly truncated; and (b) performing chromatographic separation of said CBS-containing solution using an immobilized metal affinity chromatography (IMAC) resin charged with a divalent metal ion.

It is a particular advantage of this invention that purification of recombinant, full-length or 20 truncated CBS, particularly human CBS, can be achieved without further modification of the protein, *e.g.*, by incorporating a "tag" molecule known in the art (poly-HIS, FLAG, etc.). Use of the chromatographic methods disclosed herein advantageously makes these tags unnecessary, thus avoiding additional recombinant manipulation and any disadvantages (in immunogenicity,

in vivo half-life or biochemical activity) that might be introduced into any preparation of recombinant CBS containing such a tag.

In another aspect, the invention provides methods purifying cystathionine  $\beta$ -Synthase (CBS) protein, wherein the CBS protein is a naturally occurring, chemically cleaved or genetically engineered truncated CBS protein, comprising the steps of: (a) providing a CBS-containing solution comprising one or a plurality of impurities; (b) first performing chromatographic separation of the CBS-containing solution using an ion exchange chromatography column; and (c) second performing chromatographic separation using a metal affinity chromatography (IMAC) resin, wherein the impurities are removed thereby.

Specific preferred embodiments of the invention will become evident from the following more detailed description of certain preferred embodiments and the claims.

#### **Brief Description of Drawings**

The following detailed description of the embodiments of the present invention can be best understood when read in conjunction with the following drawings.

**Fig. 1** is a purification train summary from scale-up generation runs using a multi-step chromatography method including DEAE-Sepharose-FF, Zn-IMAC and HIC chromatography.

**Fig. 2** is a purification summary from purification experiments using a DEAE-Sepharose-FF column and CBS purified using the “non-optimized” bacterial expression construct. Mobile phases included 10% ethylene glycol in addition to other components as set forth in the Examples.

**Fig. 3** is a purification train summary from scale-up generation runs using a multi-step chromatography method including DEAE-Sepharose-FF, Zn-IMAC, ceramic hydroxyapatite resin and HIC chromatography.

2013240003 06 Apr 2018

**Fig. 4** is a photoimage of a SDS page gel showing the relative amounts of CBS protein and impurities for each stage of the purification step using a DEAE column.

**Fig. 5** is a photoimage of a SDS page gel showing the relative amounts of CBS protein and impurities for a 3 column purification method including: a DEAE column, a Zn-IMAC column and HIC column.

**[TEXT CONTINUED ON PAGE 10]**

**Fig. 6** is a photoimage of a SDS page gel showing the relative amounts of CBS protein and impurities for a 4 column purification method including: a DEAE column, a Zn-IMAC column, a ceramic hydroxyapatite resin and a HIC column.

5 **Fig. 7** is chromatograms demonstrating the components of the separated mixture following purification using Zn-IMAC.

**Fig. 8** is a purification summary from development runs using a Ni-IMAC column.

**Fig. 9** is a summary table demonstrating the total protein following a purification method using a Ni-IMAC column.

10 **Fig. 10** is a photoimage of a SDS page gel showing the relative amounts of CBS protein and impurities for each stage of the purification step using a Ni-IMAC column.

**Fig. 11** is a purification summary from scale-up generation runs using a Cu-IMAC column.

**Fig. 12** is a summary table demonstrating the total protein following a purification method using a Zn-IMAC column.

15 **Fig. 13** is a photoimage of a SDS page gel showing the relative amounts of CBS protein and impurities for each stage of the purification step using a Zn-IMAC column.

**Fig. 14** is a scheme of the purification method using multi-step chromatography purification steps.

### Detailed Description of the Invention

20 This invention provides methods for purification of CBS protein, wherein said CBS protein is a naturally occurring truncated variant, or a chemically cleaved or genetically engineered truncate thereof, and particularly a truncated protein CBS produced in recombinant cells. In particular, the invention provides methods for the purification of a CBS protein that include the steps (a) providing a CBS-containing solution in the presence of at least one

impurity; and (b) performing chromatographic separation of said CBS-containing solution using a metal affinity chromatography (IMAC) resin. In additional particular embodiments, the method comprises the steps of: (a) providing a CBS-containing solution in the presence of at least one impurity; and (b) performing chromatographic separation of said CBS-containing 5 solution using an ion exchange chromatography column and a metal affinity chromatography (IMAC) resin.

A particular chromatographic separation step in the certain embodiments of the methods provided by this invention comprises an ion exchange chromatography column. In one embodiment, the ion exchange chromatography column is an anion exchanger, preferably a weak 10 anion exchanger. Various types of anion exchange resins can be used, including DEAE-Sephadex, QAE-Sephadex, DEAE-Sephacel, DEAE-cellulose and DEAE-Sepharose-FF. According to one embodiment, the anion exchange resin is DEAE-Sepharose-FF.

Another particular chromatographic separation step in the certain of the methods provided by this invention comprises a metal affinity chromatography (IMAC) resin having 15 appropriate pH and conductivity such to allow the protein to bind to the column while selective intermediate washes are used to remove weaker binding proteins and other molecular species. In certain embodiments, varying concentrations of imidazole were used to modulate the partitioning during the chromatography. Suitable metal affinity resins include immobilized metal affinity columns charged with a divalent metal ion including nickel, copper, cobalt or zinc. In certain 20 embodiments of the methods of the invention, the metal affinity chromatography (IMAC) column is used following ion exchange chromatography. In such embodiments, the IMAC column is preferably charge with zinc as a divalent cation. In other embodiments of the

inventive methods, the IMAC column is used as an initial chromatographic step. In such embodiments, nickel or copper divalent cations are preferably used to charge the IMAC column.

Additional chromatographic steps provided in certain embodiments of the methods of this invention for purifying CBS from a CBS-containing solution include without limitation 5 hydrophobic interaction chromatography (HIC). HIC is useful for removing impurities that have relatively closely related chromatographic properties that are eluted together with the target protein during the capture step.

Further additional chromatographic steps provided in certain embodiments of the methods of this invention for purifying CBS from a CBS-containing solution include without 10 limitation a ceramic hydroxyapatite resin. "Ceramic hydroxyapatite" or "CHAP" refers to an insoluble hydroxylated calcium phosphate of the formula  $(Ca_{10}(PO_4)_6(OH)_2$ ), which has been sintered at high temperatures into a spherical, macroporous ceramic form. The methods of the invention also can be used with hydroxyapatite resin that is loose or packed in a column. The choice of column dimensions can be determined by the skilled artisan.

15 Chromatography matrices useful in the method of the invention are materials capable of binding biochemical compounds, preferably proteins, nucleic acids, and/or endotoxins, wherein the affinity of said biochemical compounds to said chromatography matrix is influenced by the ion composition of the surrounding solution (buffer). Controlling the ion composition of said solution allows to use the chromatography materials of the invention either in subtractive mode 20 (CBS passes through said chromatography matrix, at least certain contaminants bind to said chromatography matrix) or, preferably, in adsorptive mode (CBS binds to the chromatography matrix).

In particular embodiments, the method for purification comprises the step of homogenizing host cells, particularly recombinant cells and in certain embodiments, recombinant cells producing mammalian, preferable human, CBS protein, wherein said recombinant construct encodes a CBS protein that is a naturally occurring truncated variant, or a 5 genetically engineered truncate thereof, and particularly wherein said construct has been optimized for recombinant cell expression. In particular embodiments, said recombinant cells are microbial cells and particularly bacterial cells. In certain particular embodiments, the bacterial cells are *E. coli* cells and the CBS sequence has been engineered in the recombinant expression construct to be optimized for expression in said cells; a specific embodiment of such 10 a nucleic acid sequence optimized for CBS expression in *E. coli* is set forth in SEQ ID NO: 4. In said methods, cells are harvested, *e.g.* by centrifugation, and optionally stored at -80 degree °C. Homogenization of host cells is performed by disrupting the cells host using physical, chemical or enzymatic means or by a combination thereof. Advantageously, for purification from 15 bacterial sources homogenation is performed by disrupting the cell wall of said bacterial host by sonication. Alternatively or additionally homogenizing is performed by destabilizing the bacterial cell wall of the host by exposure to a cell wall degrading enzyme such as lysozyme.

The methods of the invention can further comprise a clarified CBS homogenate, wherein cell debris is removed from the homogenate by either filtration or centrifugation. In certain embodiments, clarifying is performed by centrifuging the homogenate at an effective rotational 20 speed. The required centrifugation time depends *inter alia* on the volume of the homogenate, which can be determined empirically to obtain a sufficiently solid pellet. To obtain an essentially cell debris-free clarified homogenate a combination of centrifugation and filtration can be performed on the homogenate.

The term "recombinant cell" as used herein refers to suitable cells (including progeny of such cells) from any species into which has been introduced a recombinant expression construct capable of expressing a nucleic acid encoding CBS protein, preferably human CBS protein and most particularly a human CBS protein that is a naturally occurring truncated variant, or a 5 chemically cleaved or genetically engineered truncate thereof. In specific embodiments, the truncated CBS protein encoded by said recombinant expression construct has an amino acid sequence as set forth in SEQ ID NO: 3.

The term, "bacterial cell", as used herein refers to bacteria that produces a mammalian, preferably human, CBS protein *inter alia* using recombinant genetic methods including progeny 10 of said recombinant cell, wherein said CBS protein is a naturally occurring truncated variant, or a genetically engineered truncate thereof.

The term "recombinant expression construct" as used herein refers to a nucleic acid having a nucleotide sequence of a mammalian, preferably human, CBS protein, and sequences sufficient to direct the synthesis of CBS protein in cultures of cells into which the recombinant 15 expression construct is introduced and the progeny thereof.

As used herein, reference to CBS protein or polypeptide preferably includes a naturally occurring truncated variant, or a chemically cleaved or genetically engineered truncate thereof, or fusion proteins, or any homologue (variant, mutant) thereof, and specifically mammalian CBS and preferably human CBS. Such a CBS protein can include, but is not limited to, purified CBS 20 protein, recombinantly produced CBS protein, soluble CBS protein, insoluble CBS protein, and isolated CBS protein associated with other proteins. In addition, a "human CBS protein" refers to a CBS protein from a human (*Homo sapiens*) preferably includes a naturally occurring truncated variant, or a chemically cleaved or genetically engineered truncate thereof., As such, a

human CBS protein can include purified, partially purified, recombinant, mutated/modified and synthetic proteins. As disclosed herein and in related U.S. Patent No. 8,007,787 and 7,485,307, the CBS protein truncates are advantageously soluble CBS proteins that are produced in bacteria without the creation of insoluble inclusion bodies.

5 As used herein, the term "homologue" (or variant or mutant) is used to refer to a protein or peptide which differs from a naturally occurring protein or peptide (*i.e.*, the "prototype" or "wild-type" protein) by modifications to the naturally occurring protein or peptide, but which maintains the basic protein and side chain structure of the naturally occurring form. Such changes include, but are not limited to: changes in one, few, or even several amino acid side 10 chains; changes in one, few or several amino acids, including deletions (*e.g.*, a truncated version of the protein or peptide), insertions and/or substitutions; changes in stereochemistry of one or a few atoms; and/or minor derivatizations, including but not limited to: methylation, glycosylation, phosphorylation, acetylation, myristylation, prenylation, palmitation, amidation and/or addition of glycosylphosphatidyl inositol. A homologue can have enhanced, decreased, changed, or 15 substantially similar properties as compared to the naturally occurring protein or peptide. A homologue can include an agonist of a protein or an antagonist of a protein.

Homologues can be the result of natural allelic variation or natural mutation. A naturally occurring allelic variant of a nucleic acid encoding a protein is a gene that occurs at essentially the same locus (or loci) in the genome as the gene which encodes such protein, but which, due to 20 natural variations caused by, for example, mutation or recombination, has a similar but not identical sequence. Allelic variants typically encode proteins having similar activity to that of the protein encoded by the gene to which they are being compared. One class of allelic variants can encode the same protein but have different nucleic acid sequences due to the degeneracy of the

genetic code. Allelic variants can also comprise alterations in the 5' or 3' untranslated regions of the gene (e.g., in regulatory control regions). Allelic variants are well known to those skilled in the art.

Homologues can be produced using techniques known in the art for the production of 5 proteins including, but not limited to, direct modifications to the isolated, naturally occurring protein, direct protein synthesis, or modifications to the nucleic acid sequence encoding the protein using, for example, classic or recombinant DNA techniques to effect random or targeted mutagenesis. CBS variants are described in U.S. Patent No. 8,007,787, which is incorporated herein by reference in its entirety; in particular and preferred embodiments, the reagents and 10 methods of the invention set forth herein preferably include a naturally occurring truncated variant, or a chemically cleaved or genetically engineered truncate of human CBS protein. Particular truncated forms of SEQ ID NO: 3 according to the present invention include N-terminal deletion variants, C-terminal deletion variants, and variants having both N-terminal and C-terminal deletions.

15 As used herein, "substantially pure" refers to a purity that allows for the effective use of the protein *in vitro*, *ex vivo* or *in vivo*. For a protein to be useful *in vitro*, *ex vivo* or *in vivo*, it is preferably substantially free of contaminants, other proteins and/or chemicals that might interfere or that would interfere with its use, or that at least would be undesirable for inclusion with a CBS protein (including homologues thereof).

20 As used herein an enriched CBS solution is a solution subjected to one or more purification steps.

The purity of protein can be determined by calculating fold purification, *i.e.* a formula that provides a measure of how much more a purified solution is compared to a less purified solution or crude extract. Fold purification is calculated using the following formula:

$$\text{Specific activity final fraction}/\text{Specific activity crude fraction}.$$

5 Another measurement to assess purity is the “specific activity” which measures the purity of an enzyme. Specific activity can be measured using the following formula:

$$\frac{\text{Units}}{\text{mL}} \times \frac{\text{mL}}{\text{mg}} = \frac{\text{Units}}{\text{mg}}$$

10 CBS protein compositions provided by this invention are useful for regulating biological processes and particularly, processes associated with the catalysis of the pyridoxal 5'-phosphate (PLP)-dependent condensation of serine and homocysteine to form cystathionine. In particular, compositions of the present invention are useful for producing cystathionine and cysteine *in vitro* or for treating a patient that will benefit from increased CBS activity (*e.g.*, a patient with 15 homocystinuria). In certain embodiments, the invention provides said compositions of CBS protein, preferably human CBS protein, wherein said CBS protein is a naturally occurring truncated variant, or a chemically cleaved or genetically engineered truncate of human CBS protein, as pharmaceutical compositions comprising said CBS protein and a pharmaceutically acceptable carrier.

20 As used herein, a "pharmaceutically acceptable carrier" includes pharmaceutically acceptable excipients and/or pharmaceutically acceptable delivery vehicles, suitable for use in suitable administration of the composition *in vitro*, *ex vivo* or *in vivo*. Suitable *in vitro*, *in vivo* or *ex vivo* administration preferably comprises any site where it is desirable to regulate CBS activity. Suitable pharmaceutically acceptable carriers are capable of maintaining a CBS protein

as provided by this invention in a form that, upon arrival of the protein at the target cell or tissue in a culture or in patient, the protein has its expected or desired biological activity. Examples of pharmaceutically acceptable carriers include, but are not limited to water, phosphate buffered saline, Ringer's solution, dextrose solution, serum-containing solutions, Hank's solution, other aqueous physiologically balanced solutions, oils, esters and glycols. Aqueous carriers can contain suitable auxiliary substances required to approximate the physiological conditions of the recipient, for example, by enhancing chemical stability and isotonicity. Compositions of the present invention can be sterilized by conventional methods and/or lyophilized.

Throughout the specification and claims, unless the context requires otherwise, the word "comprise" or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers.

Each reference described and/or cited herein is incorporated by reference in its entirety.

The following examples are provided for the purpose of illustration and are not intended to limit the scope of the present invention.

### **Examples**

#### **Example 1: Production of Truncated CBS Protein in Bacteria**

A truncated human CBS variant lacking specific portions of the non-conserved regions (r-hC $\beta$ S $\Delta$ C; SEQ ID No: 3) were constructed and over-expressed using the previously described *E. coli* based expression system (Kozich and Kraus, 1992, *supra*). In the modification of this system disclosed herein (*i.e.*, expressing the truncate rather than the full-

length CBS protein), the CBS truncate encoded by SEQ ID NO: 3 was expressed without any fusion partner under the control of the *tac* promoter. Constructs encoding the truncated human CBS protein variant r-hC $\beta$ S $\Delta$ C (SEQ ID NO: 4) were generated by a modification of the previously described pHCS3 CBS expression construct (Kozich and Kraus, 1992, *Hum. Mutat.* 1,113-123) which contains the CBS full-length coding sequence (SEQ ID NO: 1) cloned into pKK388.1. In this construct, CBS

**[TEXT CONTINUES ON PAGE 19]**

expression was governed by the IPTG inducible *lac* promoter. To generate C-terminal deletion constructs, CBS cDNA fragments spanning the desired nucleotide residues were amplified using primers incorporating Sph I and Kpn I sites to the 5' and 3' respective ends of the PCR product. All PCR products were then cut with Sph I and Kpn I and cloned by ligation into the pHCS3  
5 vector digested with Sph I and Kpn I. An Sph I site naturally occurs in the CBS cDNA, just upstream of the antisense primer hybridization site (base pair position 1012, according to the CBS cDNA numbering, ref. 25). PCR products thus generated were then digested with Nco I and Sph I and ligated into the pHCS3 plasmid cut with the same enzymes.

pKK CBS Δ414-551

10 sense: CGTAGAATTCACCTTGCCCGCATGCTGAT (SphI)(SEQ ID NO: 5)

antisense: TACGGGTACCTCAACGGAGGTGCCACCACCAGGGC (KpnI)(SEQ ID NO: 6)

Finally, the construct was transformed into *E. coli* BL21 (Stratagene). The authenticity of the construct was verified by DNA sequencing using a Thermo Sequenase Cy5.5 sequencing kit (Amersham Pharmacia Biotech) and the Visible Genetics Long-Read Tower System-V3.1 DNA  
15 sequencer according to the manufacturer's instructions.

*Bacterial Expression analysis of CBS Deletion Mutants-Growth of E. coli.* BL21 cells bearing the CBS truncation mutant construct, induction of expression and the generation of crude cell lysates were performed as described previously (Maclean *et al.*, 2002, *Hum. Mutat.* 19(6), 641-55). Briefly, bacteria were grown at 37° C aerobically in 1 L NZCYMT media  
20 (Gibco/BRL, Gaithersburg, Md.) containing 75 µg/mL ampicillin and 0.001% thiamine in the presence or absence of 0.3 mM δ-aminolevulinate (δ-ALA) until they reached turbidity of 0.5 at 600 nm. IPTG was then added to 0.5 mM and the bacteria were grown further. The insoluble fraction was prepared as follows: after the centrifugation of the sonicated homogenate, pelleted

cell debris were thoroughly washed with chilled 1x Tris-buffered saline, pH 8.0. The pellets were then resuspended in 1ml of the lysis buffer (Maclean *et al.*, *ibid.*) followed by a brief sonication in order to homogenize the insoluble fraction.

*CBS Activity Assay-* CBS activity was determined by a previously described radioisotope assay using [<sup>14</sup>C] serine as the labeled substrate (Kraus, 1987, *Methods Enzymol.* 143,388-394). Protein concentrations were determined by the Lowry procedure (Lowry *et al.*, 1951, *J. Biol. Chem.* 193, 265-275) using bovine serum albumin (BSA) as a standard. One unit of activity is defined as the amount of CBS that catalyzes the formation of 1  $\mu$ mol of cystathionine in 1 h at 37°C.

*Denaturing and Native Polyacrylamide Gel Electrophoresis and Western Blotting-* Western blot analysis of crude cell lysates under both denaturing and native conditions was performed as described previously (Janosik, 2001, *supra*) with some modifications. Soluble fractions of *E. coli* lysates containing the expressed mutant protein were mixed with sample buffer and run on a 6% native PAGE without a stacking gel. The final composition of the sample buffer was: 50mM Tris-HCl, pH 8.9, 1mM DTT, 10% glycerol, 0.001% bromphenol blue. Detection of heme was performed using a previously described method that relies on heme peroxidase activity (Vargas *et al.*, 1993, *Anal. Biochem.* 209(2), 323-6).

*Densitometric Scanning Analysis-Quantitative* densitometry analysis was performed using the Imagemaster ID (version 2.0) software (Pharmacia). To construct a calibration curve, 50, 75, 100, 250, 500 and 1000ng of purified wild type CBS protein were run on an SDS-PAGE together with crude cell lysates of the individual mutants. Following electrophoresis, Western blot immunoanalysis was conducted using rabbit anti-CBS serum. The signals corresponding to

the experimentally observed CBS mutant subunits were all within the linear range of the calibration curve constructed with purified human CBS.

### **Example 2: Preparation of Crude Extraction**

Crude CBS protein-containing extracts was prepared for use in downstream chromatography steps. Frozen pellets (cells) obtained from fermentation of recombinant bacteria producing human truncated CBS variant (r-hC $\beta$ S $\Delta$ C; SEQ ID No: 3) were lysed, wherein said bacteria expressed truncated human CBS encoded by SEQ ID NO: 4. Lysis buffer for initial isolations contained 1 mM DTT, 1% Triton X-100, and Protease Inhibitor. These components were eventually removed from the buffer. The buffer used for the final isolations that produced material for scale-up runs consisted of 20mM Sodium Phosphate, 50 mM NaCl, 0.1 mM PLP (pH 7.2), with lysozyme added to a concentration of 2 mg/mL after homogenization. Following mixing with lysozyme for 1 hr at 4°C, the homogenate was sonicated until viscosity was reduced and then subjected to centrifugation at 20,000 rpm (48,000 x g) for 30 min. The supernatant was collected, aliquoted, and stored at -70°C until use. Generally, the crude extract was thawed at 37°C prior to chromatographic purification.

### **Example 3: DEAE-Sepharose FF Chromatography**

DEAE-Sepharose FF was used in this Example of the purification methods for CBS because it possesses good capacity and flow properties and has been manufactured consistently for several years. This step employed a drip/gravity column that contained approximately 6 mL of resin. The column was equilibrated in Sodium Phosphate buffer with 50 mM NaCl, pH 7.0. Loading of the crude extract was targeted at approximately 20 mg total protein/mL resin. After loading the column, the red color of the load was concentrated near the top of the column.

Following a wash with equilibration buffer, the column was washed with a buffer containing 150 mm NaCl, whereby the majority of color eluted from the column (all steps were performed at pH 7.0). Essentially all color was removed from the column with a 300mM NaCl wash. Based on these results, a column was packed that could be operated in flow mode. The conditions 5 employed equilibration/loading at a NaCl concentration 50mM, with elution at 250mM NaCl. The final conditions required dilution of the column load with H<sub>2</sub>O to approach the ionic strength of the equilibration/wash buffer (50mM NaCl), and elution with 137 mM NaCl (Figs. 1, 2 and 3). Samples were analyzed by SDS-PAGE to determine the relative amounts of CBS protein and 10 impurities (Fig. 4). The following tables represent column operational parameters and data from the scale-up runs that employed them.

**Table 1. Operational Parameters for DEAE Capture Step**

Process Step	Column load target (total protein mg/mL)	NaCl Concentration (with 20mM Na <sub>3</sub> PO <sub>4</sub> pH 7.0)	Column Volumes (mL)	Contact time Column vol./flow rate (min.)
Equilibration	N/A	50 mM	3-5	10
Load	20-25 mg/mL	Approx. 50 mM	Variable	15
Wash	N/A	50 mM	3	10
Elution	N/A	137 mM	Variable*	15
2M NaCl Strip	N/A	2 M	3	10

\* Note: Eluate collection starts at approx. 0.4 AU and ends at approx. 0.55 AU. Void volume typically approx. 1 column volume.

15

**Table 2. Data from Scale-up Runs (n=6)**

Input		Output		
Column loading (per mL Resin)				
Total Protein (mg)	Units	Recovery (%)	Fold Purif. (By S.A.)	
14.5 - 19.8	3275 - 5443	79.3 - 93.0	2.5 - 3.3	Range
18.2	4451	86	2.8	Average

#### Example 4: IMAC Chromatography

The ability for an immobilized metal affinity column (IMAC) to separate CBS protein from impurities and other contaminants from a biological source, such as a recombinant bacterial cell homogenate, was demonstrated. Because of the desire to avoid low pH conditions (< 5, 5 anecdotal), varying concentrations of imidazole were used to modulate partitioning during the chromatography.

Copper ( $\text{Cu}^{++}$ ) was tested as a candidate species of IMAC column based on its relatively strong binding characteristics. Prior to being applied to the IMAC column, the CBS solution was adjusted to 0.4M NaCl. The results indicated that capture was near complete, with an acceptable 10 activity recovery (70-80%). Recovery of CBS was obtained using 100mM imidazole, which resulted in significant precipitation upon thawing from storage at -70° C. (Fig. 11). In addition, there was only a small increase in purity relative to the load. Thus, experiments employing 15  $\text{Ni}^{++}$ IMAC were conducted as the metal of choice. In these experiments, the CBS sample was run through a G-25 column to remove dithiothreitol (DTT) prior to loading the solution onto the IMAC column. Purity enhancement remained low and selectivity was similar to  $\text{Cu}^{++}$ , as evidenced by a relatively small  $A_{280}$  peak in the high imidazole strip fraction. (Figs 8, 9 and 10).

The relatively weak binding  $\text{Zn}^{++}$  was also tested. Although capture, wash and elution conditions required significantly lower imidazole concentrations, potential for purity enhancement provided positive results due to the significant size of the  $A_{280}$  peaks in the post-20 load wash and high imidazole strip fractions. 0.4 M NaCl and 0.01% Triton X-100 were added to the equilibration and wash buffers to minimize non-specific binding. (Figs. 1 and 3). Samples were analyzed by SDS-PAGE to determine the relative amounts of CBS protein and impurities

(Fig. 13). The results of the IMAC experiments are presented in Fig. 7. The following tables represent column operational parameters and data from the scale-up runs that employed them.

**Table 3. Operational Parameters for Zn-IMAC Step**

Process Step	Column load target (total protein mg/mL)	Imidazole Concentration (with 20mM Na <sub>3</sub> PO <sub>4</sub> pH 7.0)	Column Volumes (mL)	Contact time Column vol./flow rate (min.)
Equilibration	N/A	1 mM	3	10
Load	10	0	Variable	10
Wash	N/A	1 mM	3	10
Elution	N/A	11 mM	Variable*	10
Strip	N/A	100 mM	3	10

5 \* Note: Eluate collection starts at approx. 0.25 AU and ends at approx. 0.16 AU. Void volume typically approx. 1.5 column volumes.

**Table 4. Data from Scale-up Runs (n=5)**

Input		Output		
Column loading (per mL Resin)				
Total Protein (mg)	Units	Recovery (%)	Fold Purif. (By S.A.)	
6.5-9.3	4414-7038	71.8 – 84.6	1.3 -1.6	Range
8.1	5687	80	1.4	Average

10

### 15 Example 5: HIC Chromatography

Multiple experiments were conducted to identify the parameters for HIC chromatography. Initial drip column experiments were conducted that employed a resin with a relatively strong binding ligand (phenyl) with an IMAC eluate as starting material/load. This 20 experiment resulted in empirically complete binding at 1.3M (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>. However, there was evidence of significant retention of CBS on the column even after washing with a low ionic

strength buffer. Based on these results, a resin with a weaker binding ligand (butyl) was tested. Initial experiments with this resin showed no apparent capture at 0.5M (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>. The non-binding flow through of this column experiment was collected and adjusted to 1.25M (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, and reloaded on to a column equilibrated to the same concentration of (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>. In 5 this case there was evidence of significant binding to the column. A 20 column volume (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> gradient elution was performed from 1.25M to 0.25M (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> with fractions collected. SDS-PAGE analysis of the fractions indicated that there was significant potential for impurity clearance on the lower end of the gradient. Experiments utilizing step gradient washes at varying concentrations of (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> determined the final operational parameters. (Figs. 1 and 10 3). Those parameters and the scale-up run data are summarized in the tables below.

**Table 5. Operational parameters for HIC Step (n=6)**

Process Step	Column load target (total protein mg/mL)	(NH <sub>4</sub> ) <sub>2</sub> SO <sub>4</sub> Concentration (with 20mM Na <sub>3</sub> PO <sub>4</sub> pH 7.0)	Column Volumes (mL)	Contact time Column vol./flow rate (min.)
Equilibration	N/A	1.4M	3	10
Load	5-10	1.4M	Variable	10
Wash	N/A	1.4M	3	10
Elution	N/A	1.1M	Variable*	10
Strip	N/A	0.05M NaCl	3	10

\* Note: Eluate collection starts at approx. 0.25 AU and ends at approx. 0.15 AU. Void volume typically approx. 1.4 column volumes.

15

**Table 6. Data from Scale-up Runs (n=5)**

Input		Output			
Column loading (per mL Resin)					
Total Protein (mg)	Units	Recovery (%)	Fold Purif. (By S.A.)		
5.1 - 7.2	5375 - 9248	77.8 - 92.7	1.0 - 1.3	Range	
6.3	7638	85	1.2	Average	

### Example 6: CHAP Chromatography

Ceramic hydroxyapatite is a resin that has a unique, potentially mixed binding mode chemistry that was utilized in a CBS purification method. CBS displayed acidic characteristics and therefore initial investigation focused on using phosphate-modulated partitioning. The initial 5 experiments utilized HIC eluate that was buffer exchanged into a 0.05M NaCl, 0.005M Potassium Phosphate (pH 6.8) buffer. A 5 mL ceramic hydroxyapatite (Type 1) cartridge was equilibrated in the same buffer and the conditioned HIC eluate was loaded onto the column. There was no visible breakthrough of protein (as measured by  $A_{280}$ ) during the load and subsequent wash with equilibration/wash buffer. A linear gradient (5%) of 0.005M to 0.5M 10 Potassium Phosphate was then run and fractions were collected. Based on the chromatogram, samples were analyzed by SDS-PAGE to determine the relative amounts of CBS protein and impurities. In subsequent experiments (based on analysis of the results of previous experiments), step washes with varying levels of phosphate were employed to determine optimal conditions for load, wash, and elution steps. In addition, the composition of buffer salts was transitioned from 15 Potassium to Sodium Phosphate. (Fig. 3). The following tables represent column operational parameters and data from the scale-up runs that employed them.

**Table 7. Operational Parameters for CHAP Step**

Process Step	Column load target (total protein mg/mL)	Na <sub>3</sub> PO <sub>4</sub> Concentration (with 50mM NaCl, pH 7.0)	Column Volumes (mL)	Contact time Column vol./flow rate (min.)
Equilibration	N/A	10 mM	3	6
Load	10-15	10 mM	Variable	6
Wash	N/A	30 mM	3	6
Elution	N/A	90 mM	Variable*	6
Strip	N/A	150 mM	3	6

\* Note: Eluate collection starts at approx. 0.20 AU and ends at approx. 0.16 AU. Void volume typically approx. 1.0 column volumes.

**Table 8. Data from Scale-up Runs (n=5)**

Input		Output		
Column loading (per mL Resin)		Output		
Total Protein (mg)	Units	Recovery (%)	Fold Purif. (By S.A.)	
9.9 –12.2	11205 - 12297	84.6 – 92.4	1.1 -1.2	Range
11.1	11751	89	1.2	Average

## 5 Example 7: Integrated Process Results

The particular multi-step method described in these Examples was evaluated at the scale of a 60mL capture column. All of the purification trains utilized starting material (crude extract) obtained from fermentations that were seeded with recombinant cells comprising a construct comprising a truncated variant of human CBS encoded by a nucleic acid having codons optimized for expression in *E. coli*. This construct resulted in starting material that was approximately 2-fold higher in specific activity, and significantly impacted the final purity achieved from the integrated purification method. The overall purification results using the multi-step method were measured by SDS-PAGE and Specific Activity (Figs. 5 and 6). The results demonstrated that the purity and specific activity met or exceeded that of the purified tagged truncated CBS. All Specific Activities of final column eluates obtained by the largest scale currently possible exceeded 1200 U/mg total protein. The following table summarizes the overall purification results from the scale-up runs.

**Table 9. Overall Results from Scale-Up Runs**

	Total Recovery (%)		Fold Purification	
	Range	Average	Range	Average

	Total Recovery (%)		Fold Purification	
3 Column Train (n=3)	57 – 60	58	5.7 – 6.2	5.9
4 Column Train (n=2)	47 – 52	50	4.6 – 5.4	5.0

Specific Activity of Final Column Eluate = 1206 -1509.

Having described the invention in detail and by reference to specific embodiments thereof, it will be apparent that modifications and variations are possible without departing from the scope of the invention defined in the appended claims. More specifically, although some aspects of the present invention are identified herein as particularly advantageous, it is contemplated that the present invention is not necessarily limited to these particular aspects of the invention.

**Table 10: C<sub>β</sub>S Sequences**

Molecule	SEQ ID NO	Sequence
<b>Native human C<sub>β</sub>S nucleic acid sequence</b>	<b>1</b>	atgccttctgagaccccccagggcagaagtggggccacag gctccccaccgctcaggccacactcggcgaaggggag cctggagaagggtccccagaggataagaagccaaggag ccccctgtggatccggccgatgctccgagcaggtgcacct ggcagctggccggcctgcctccgagtccccacatcacca cactgccccggcaaaatctccaaaatcttgcagatatt ctgaagaaaatcggggacaccctatggtcagaatcaaca agattgggaagaagttcggcctgaagtgtgagctttggc caagtgtgagttcttcaacgcggggggggcgtgaaggac cgcatcagcctgcggatgattgaggatgctgagcgcgacg ggacgctgaagccggggacacgattatcgagccacatc cgggaacaccgggatcgggctggccctgctgcggcagtg aggggctatcgctgcatcatcgatgcggactggggctga gctccgagaagggtgacgtgtgcggcactggggctga gattgtgaggacgcccaccaatgccagggtcgactcccg gagtcacacgtgggggtggcctggcggctgaagaacgaaa tcccccaattctcacatccttagaccagtaccgcaacgc caacccctggctcactacgacaccaccgctgatgagatc ctgcagcagtgtgatggaaactggacatgctgtggctt cagtggcacggcggcaccatcacggcattgccaggaa gctgaaggagaagtgtcctggatgcaggatcattggggtg gatcccgaagggtccatcctcgagagccggaggagctga accagacggagcagacaacctacgaggttgaaggatcg ctacgacttcatccccacggtgcggacaggacgggtggt gacaagtggtaagagcaacgatgaggaggcgttacact

Molecule	SEQ ID NO	Sequence
		ttgcccgcatgctgatcgcgcaagaggggctgctgtgcgg tggcagtgcgtggcagcacggcggcgtggccgtgaaggct gcgcaggagctgcaggagggccagcgcgtgcgtggcattc tgcccgactcagtgcggaaactacatgaccaagttcttag cgacagggtggatgcgtcagaaggcttctgaaggaggag gacctcacggagaagaagccctgggtggcacctccgt ttcaggagctgggcctgtcagcccgctgaccgtgtcc gaccatcacctgtggcacaccatcgagatcctccggag aaggcgttcgaccaggcgccgtgtggatgaggcgggg taatcctggaaatggtacgcctggaaacatgctctcgt cctgcttgcggaaagggtcagccgtcagaccaagttggc aaagtcatctacaaggcgttcaaacacagatccgcctacgg acacgctggcaggctctgcacatcctggagatggacca cttcgcctgtggcgtcagcggcagatgggttcgggtgg accgggaagtccagtcagcggcagatgggttcgggtgg tcaccgcattgacttgcgaacttcgtggcccgccagga gcgggaccagaagtga
<b>Native human C<math>\beta</math>S polypeptide sequence</b>	<b>2</b>	MPSETPQAEVGPTGCPHRSGPHSAKGSLEKGSPEDKEAKE PLWIRPDAPSRCTWQLGRPASESPHHHTAPAKSPKILPDI LKKIGDTPMVRINKIGKKFGLKCELLAKCEFFNAGGSVKD RISLRMIEDAERDGTTLKPGDTIIEPTSGNTGIGLALAAAV RGYRCIIVMPEKMSSEKVDVLRALGAEIVRPTPTNARFDSP ESHVGVAWRLKNEIPNSHILDQYRNASNPLAHYDTTADEI LQQCDGKLDMLVASVGTGGITGIARKLKEKCPGCRIIGV DPEGSILAEPEELNQTEQTTYEVEGIGYDFIPTVLDRTVV DKWFKSNDEEAFTFARMLIAQEGLLCGGSAGSTVAVAVKA AQELQEGQRCCVVLIPDSVRNYMTKFLSDRWMLQKGFLKEE DLTEKKPWWHRLRQELGLSAPLTVLPTITCGHTIEILRE KGFDQAPVVDEAGVILGMVTLGNMLSSLAGKVQPSDQVG KVIYKQFKQIRLTDLGLRSHILEMDHFALVVHEQIQQYHS TGKSSQRQMVFGVVTайдлнFVAAQERDQK

Molecule	SEQ ID NO	Sequence
<b>Truncated, Human C<math>\beta</math>S polypeptide sequence</b>	<b>3</b>	MPSETPQAEVGPTGCPHRSGPHSAKGSLEKGSPED KEAKEPLWIRPDAPSRCTWQLGRPASESPHHHTAP AKSPKILPDIKKIGDTPMVRINKIGKKFGLKCEL LAKCEFFNAGGSVKDRISLRMIEDAERDGTTLKPGD TIIIEPTSGNTGIGLALAAAVRGYRCIIVMPEKMS EKVDVLRALGAEIVRPTPTNARFDSPESHVGVAWR KNEIPNSHILDQYRNASNPLAHYDTTADEIILQQCD GKLDMLVASVGTGGITGIARKLKEKCPGCRIIGV DPEGSILAEPEELNQTEQTTYEVEGIGYDFIPTV DRTVVDWFKSNDEEAFTFARMLIAQEGLLCGGSA GSTVAVAVKAAQELQEGQRCCVVLIPDSVRNYMTK LSDRWMLQKGFLKEEDLTEKKPWWHRL
<b>Truncated, Optimized Human C<math>\beta</math>S nucleic acid sequence</b>	<b>4</b>	ATGCCGTCAAGAACCCCGCAGGCAGAAGTGGGTCCGACGG GTTGCCCGCACCGTAGCGGTCCGCATTCTGCAAAGGCAG TCTGGAAAAGGTTCCCGGAAGATAAAGAAGCCAAAGAA CCGCTGTGGATTCTGCCGGACCGCACCGTCACGCTGTACCT GGCAGCTGGGTCTGCCGGCAAGCGAATCTCCGCATCACCA TACGGCTCCGGCGAAAAGTCCGAAAATTCTGCCGGATATC

Molecule	SEQ ID NO	Sequence
		CTGAAGAAAATTGGTGACACCCGATGGTCGTATAACA AAATCGGCAAAAAATTGGCTGAAATGCGAACTGCTGGC TAAATGTGAATTTCATGCGGGCGGTTCCGTGAAAGAT CGTATCTCACTGCGCATGATTGAAGATGCTGAACGCGAC GCACCCGTAAACCGGGTGATAACGATTATCGAACCGACCTC TGGCAACACGGGTATCGGTCTGGCACTGGCGGCGCAGTC CGTGGTTATCGCTGCATTATCGTATGCCGGAAAAATGA GCTCTGAAAAAGTTGATGTCCTGCGTGCTCTGGGCGCGGA AATTGTTCGTACCCGACGAATGCCGCTTCGACAGTCCG GAATCCCATGTGGGTGTTGCATGGCGCTGAAAAACGAAA TCCCAGATTGCACTTCTGGATCAGTATCGTAACGCTAG CAATCCGCTGGCGCATTACGATACCACGCCGACGAAATC CTGCAGCAATGTGATGGCAAACCTGGACATGCTGGTCGCTT CTGTGGGTACCGGCGGTACCATTACGGGATCGCGCGTAA ACTGAAAGAAAAATGCCGGGCTGTCGATTATCGGTGTG GATCCGGAAGGCAGTATTCTGGCGAACCGGAAGAACTGA ACCAGACCGAACAAACCACGTATGAAGTTGAAGGCATCGG TTACGATTATTCCGACCGTCTGGATCGCACGGTGGTT GACAAATGGTCAAAAGCAATGACGAAGAACGCTTACCT TCGCACGTATGCTGATCGCTCAGGAAGGTCTGCTGTGCGG TGGTTCAGCAGGTTGACGGTCGCAGTGGCAGTTAAAGCT GCGCAGGAACGTCAAGAAGGTCAACGTTGTCGTGATT TGCCGGATTCTGTCGCAACTACATGACCAATTCTGAG TGACCGTTGGATGCTGCAAAAAGGCTTCCTGAAAGAAGAA GATCTGACCGAGAAAAACCGTGGTGGCACCTGCGCT AA

**CLAIMS:**

1. A method for purifying cystathionine  $\beta$ -Synthase (CBS) protein, wherein the CBS protein is a naturally occurring, chemically cleaved or genetically engineered truncated CBS protein, comprising the steps of:
  - (a) providing a CBS-containing solution comprising one or a plurality of impurities;
  - (b) first performing chromatographic separation of the CBS-containing solution using an ion exchange chromatography column; and
  - (c) second performing chromatographic separation using a metal affinity chromatography (IMAC) resin, wherein the impurities are removed thereby.
2. The method of claim 1, further comprising the step of performing chromatographic separation using a Hydrophobic Interaction Chromatography (HIC) column.
3. The method of claims 1-2, further comprising the step of performing chromatographic separation using a ceramic hydroxyapatite resin.
4. The method of claims 1-3, wherein the ion exchange chromatography column is a weak anion exchanger.
5. The method of claim 4, wherein the weak anion exchanger is a DEAE-Sepharose FF column.
6. The method of claims 1-5, wherein the metal affinity chromatography (IMAC) resin is charged with a divalent metal cation.
7. The method of claim 6, wherein the divalent metal cation is nickel, copper, cobalt or zinc.
8. The method of claims 1-7, further comprising eluting CBS protein from the metal affinity chromatography (IMAC) resin with an elution buffer comprising imidazole.
9. The method of claims 1-8, wherein the truncated CBS protein has an amino acid sequence identified by SEQ ID NO: 3.

10. The method of claims 1-9, wherein the CBS-containing solution is a clarified CBS solution.
11. The method of claims 1-10, wherein the CBS protein is produced in a recombinant cell.
12. The method of claim 11, wherein the recombinant cell is a bacterial cell.
13. The method of claim 12, wherein the CBS-containing solution is obtained by homogenizing recombinant bacterial cells expressing a recombinant construct comprising a nucleic acid sequence encoding CBS.
14. The method of claim 13, wherein the CBS nucleic acid encodes the truncated CBS protein.
15. The method of claim 14, wherein the truncated CBS protein has been truncated to an ending position of one of amino acid residues from 382-532, 382-550 or 543-550 of SEQ ID NO:2.
16. The method of claim 15, wherein the CBS nucleic acid sequence comprises SEQ ID NO. 4.
17. The method of claims 12-16, wherein the recombinant cells are *E. coli* cells.
18. The method of claim 17, wherein the nucleic acid sequence encoding the truncated CBS protein is optimized for expression in *E. coli* cells.
19. A substantially purified CBS solution produced by the method of claims 1-8.
20. The substantially purified CBS solution of claim 19 formulated in a pharmaceutically acceptable carrier.
21. A method for producing an enriched CBS solution, wherein the CBS protein is a naturally occurring, chemically cleaved or genetically engineered truncate thereof, the method comprising:

(a) providing a CBS-containing solution comprising one or a plurality of impurities; and

(b) performing chromatographic separation of the CBS-containing solution using an immobilized metal affinity chromatography (IMAC) resin charged with a divalent metal ion, wherein the impurities are removed thereby.

22. The method of claim 21, wherein the divalent metal ion is nickel, copper, cobalt or zinc.

23. The method of claims 21 - 22, wherein the CBS protein has an amino acid sequence identified by SEQ ID NO: 3.

24. The method of claims 21 - 23, wherein the CBS solution is a clarified CBS solution.

25. The method of claims 21 - 24, wherein the CBS protein is produced in a recombinant cell.

26. The method of claim 25, wherein the recombinant cell is a bacterial cell.

27. The method of claim 26, wherein the CBS solution is obtained by homogenizing recombinant bacterial cells expressing a recombinant construct comprising a nucleic acid sequence encoding the CBS protein.

28. The method of claim 27, wherein the CBS protein has been truncated to an ending position of one of amino acid residues from 382-532 or 543-550 of SEQ ID NO:2.

29. The method of claim 28, wherein the CBS nucleic acid sequence comprises SEQ ID NO. 4.

30. The method of claims 21-29, wherein the bacterial cells are *E. coli* cells.

31. The method of claims 21-30, wherein the nucleic acid sequence encoding the CBS protein is optimized for expression in *E. coli* cells.

32. An enriched CBS solution produced by the method of claims 22-34.

1/20

Figure 1A

CBS Purification Train					
DEAE-FF			Zn-IMAC (Chel Seph FF)		
HIC (Butyl-S Seph.)					
Lot No: PG-99					
Weight	CONV.	U/mL	Total U	mg/mL	Total mg
CE Pre-Spin	88.6	1.0	2655	235202	12.4
CE Post-Spin	85.2	1.0	2459	209498	11.3
Activity yield (Pre-Spin/Post-Spin)			89.1%		
Fold purification (X)			1.0		
DEAE-FF	Col. Vol.	61 mL	Column Load/ml Resin		
			Total Protein	Units	
			14.5	3275	
Weight	CONV.	U/mL	Total U	mg/mL	Total mg
LOAD	102.6	1.0	1947	199762	8.6
FT	105.2	1.0	4	427	1.9
WASH	159.7	1.0	1	197	0.8
VOID	57.6	1.0	12	716	0.2
ELUATE	47	1.0	3671	172551	6.5
ELUATE TAIL	33.7	1.0	472	15912	1.7
2M NaCl	140.8	1.0	67	9417	2.0
Fold Purification (X)			2.5		
Total Protein Accountability			Total Units Accountability		
			111%		
			100%		
Activity Rec.					
			100.0%		
			100.0%		
			0.2%		
			0.1%		
			0.4%		
			86.4%		
			8.0%		
			4.7%		
			100%		

**Figure 1B**

CBS Purification Train		HIC (Buty/ S Seph)	
DEAE-FF - Zn IMAC (Che Seph FF)		HIC (Buty/ S Seph)	
Zn IMAC	Cell Vol =	40 mL	Column Load/mL Resin
			Total Protein Units
			6.5 4414
Weight	CONV.	U/mL	Total U
LOAD	47.3	1.0	3733
FT	156	1.0	13
WASH/VOID	54.8	1.0	22
ELUATE PK 1	39.4	1.0	941
ELUATE PK 2	50.5	1.0	2158
ELUATE COMB PKS	88	1.0	1681
100 mM STRIP	86	1.0	64
Total mg	S.A.	Activity Rec.	Units
5.5	679	100.0%	100.0%
0.43	30	1.1%	
0.07	309	0.7%	
0.91	1034	21.0%	
2.10	1027	61.7%	
1.50	1121	83.8%	
0.58	111	3.1%	
Total Protein Accountability		89%	
Fold Purification (%)		1.5	

3/20

Figure 1C

CBS Purification Train DEAE-FF → Zn-IMAC (Chel. Seph. FF) → HIC (Butyl-S Seph.)							
HIC	Col. Vol.=	23 mL	Column load/mL Resin				Activity Rec.
			Total Protein	Units	Total mg	S.A.	
			6.5	6745			
LOAD	103.9	1.1	1357	155143	1.58	149	1040
FT/WASH	85	1.1	26	2470	0.080	6	400
VOID	30.5	1.1	34	1133	0.060	2	681
ELUATE	41.1	1.1	2671	120762	2.50	93	1293
STRIP	43.8	1.0	282	13591	0.87	38	357
Fold Purification (X)					Total Protein Accountability		Units Accountability
					93%		89%
Recovery Total Units From First Column Load							
60%				Total Fold Purification (X)			
10.6%				5.7			

4/20

Figure 2

RC-164 DEAE FF (DEAE-IMAC-HIC Process Train)						
	Date	04/21/11	Col. Vol.	30	Exp. No.	RC-164
	Column ID	RC-3-10	Total protein/mL resin loaded	26 mg/mL		
Fraction ID	Weight or Volume (g or mL)	CONV.	Protein (mg/mL)	Total Protein in fraction (mg)	Cystathionine from assay (nmol.mL.hr)	Dilution factor from assay
CE Pre-Spin	37.6	1.0	20.9	784.3	46423	40
CE Post-Spin	36.3	1.0	20.7	752.9	52427	40
DEAE Load	49.8	1.0	15.4	766.8	36740	40
DEAE FT	49.7	1.0	3.0	151.0	3403	1
DEAE Void	31	1.0	0.3	8.8	10298	1
DEAE Eluate	24.9	1.0	5.2	130.0	63422	40
DEAE Eluate Tail	18.9	1.0	1.9	35.16	69389	5
DEAE Wash	89.3	1.0	1.6	143.16	5519	1
DEAE 2M NaCl	76	1.0	3.2	241.44	13935	5
Mass Balance						
Buffers:			Units	99.8%	Mass Balance Units (from load)	Mass Balance Protein
Equilibration	0.02 M Na3PO4, 0.05 M NaCl, 10% Ethylene Glycol, pH 7.0			103.8%	86.3%	94.2%
Wash	0.02 M Na3PO4, 0.05 M NaCl, 10% Ethylene Glycol, pH 7.0					
Elution	0.02 M Na3PO4, 0.137 M NaCl, 10% Ethylene Glycol, pH 7.0					
Strip	2 M NaCl					
Sanitize	1.0 M NaOH					

5/20

CBS Purification Train DEAE-FF → Zn-MAC (Che-Sep FF) → HAP (Ceramic Type) → HIC (Bintyl S Seph)						
Lot No: RC-1-103						
CE	Weight	CONV.	U/mL	Total U	mg/mL	Total mg
Pre-Spin	87.1	1.0	3369	293422	13.9	1211
Post-Spin	100.4	1.0	3050	306270	11.7	1175
Activity yield (Pre-Spin/Post Spin)	104.4%					
Fold purification (X)	1.1					
DEAE-FF	Col. Vol.	60 mL		Column load/mL Resin		
				Total Protein	Units	
				19.6	5105	
LOAD*	Weight	CONV.	U/mL	Total U	mg/mL	Total mg
FT	100.4	1.0	3050	306270	11.7	1175
WASH	102.6	1.0	6	585	2.3	236
VOID	164.6	1.0	2	410	1.0	165
ELUATE	56.3	1.0	11	644	0.3	17
ELUATE TAIL	52.6	1.0	4976	261744	7.2	379
2M NaCl	30.6	1.0	441	13488	1.3	40
Fold Purification (X)	2.7			Total Protein	Total Units Accountability	
*Load same as Post-Spin;	*Load occurred during balancing of tubes for centrifugation			101%	93%	


6/20

**CBS Purification Train**  
**DEAE-FF → Zn-IMAC (Chel. Seph. FF) → HAP (Ceramic Type 1) → HIC (Butyl-S Seph.)**

Zn-IMAC		Col. Vol. =	40 mL	Column load/mL Resin		Total mg		S.A.		Activity Rec.	
Weight	CONV.	U/mL	Total U	mg/mL	Total mg	mg/mL	Total mg	S.A.	Activity Rec.		
LOAD	52.9	1.0	4792	253492	7.0	370	685	100.0%	100.0%		
FT/WASH	144.9	1.0	23	3388	0.65	94	36	1.3%	1.3%		
VOID	52.3	1.0	64	3355	0.16	8	401	1.3%	1.3%		
ELUATE COMB PKS	82.6	1.0	2457	202919	2.67	221	920	80.0%	80.0%		
100 mM STRIP*	89	1.0	19	1689	0.15	13	127	0.7%	0.7%		
Fold Purification (X)		1.3		Total Protein Accountability		Total Protein Accountability		Units Accountability			
*Precipitation observed in strip sample.				91%		91%		83%			
HAP		Col. Vol. =	18 mL	Column load/mL Resin		Total mg		S.A.		Activity Rec.	
				Total Protein		Units					
				12.2		11205					
LOAD		CONV.	U/mL	Total U	mg/mL	Total mg	mg/mL	Total mg	S.A.	Activity Rec.	
LOAD		82.1	1.0	2457	201691	2.67	219	920	100.0%		
FT/WASH		132.2	1.0	26	3383	0.08	11	320	1.7%		
ELUATE		37.5	1.0	4552	170694	4.34	163	1049	84.6%		
STRIP		34.5	1.0	348	12013	0.55	19	633	6.0%		
Fold Purification (X)		1.1		Total Protein Accountability		Total Protein Accountability		Units Accountability			
				88%		88%		92%			

7/20

CBS Purification Train						
DEAE-FF → Zn-IMAC (Chel. Seph. FF) → HAP (Ceramic Type 1) → HIC (Butyl-S Seph.)						
HIC	Col. Vol.=	21 mL	Column load/mL Resin			
			Total Protein	Units		
			7.2	8447		
Weight	CONV.	U/mL	Total U	mg/mL	Total mg	S.A.
LOAD	43.8	1.1	3682	177384	3.82	1166
FT/WASH	105.7	1.1	1	96	0.020	50
VOID	28.7	1.1	4	126	0.020	241
ELUATE	44.9	1.1	3251	160544	3.26	133
STRIP	40.2	1.0	325	14375	0.54	22
Fold Purification (X)	1.0				Total Protein Accountability	Units
					103%	Accountability
						99%
Recovery Total Units						
From First Column Load						
				52%		
					Total	
					Fold	
					Purification (X)	
					4.6	

**Figure 4**




Figure 5






Figure 6

**Figure 7A**

12/20

Figure 7B



13/20

	Date	04/06/11
Column ID	RC-3-	
Col. Vol.		9
Total protein/mL resin loaded	29	mg/mL

Figure 8

Fraction ID	Weight or Volume (g or mL)	CONV.	Total Protein in fraction (mg)	Cystathione from assay (nmol.mL.hr)	Dilution factor from assay	Total Units in fraction	S.A. Fraction	% Rec. Units (%)	% Rec. Total Protein (%)
CE	16	1.0	15.3	244.1	76039	20	24332	100	100.0%
IMAC Load	34.7	1.0	7.6	264.7	40808	20	28321	107	116.4%
IMAC FT	34.3	1.0	2.3	77.9	50	20	34	0	0.1%
IMAC Equil Wash	32.6	1.0	2.8	91.6	4111	1	134	1	0.5%
IMAC 5mM Imid.	34.3	1.0	0.6	19.2	9211	1	316	16	1.1%
IMAC Void	6.9	1.0	0.4	3.0	3813	1	264	89	0.9%
IMAC Eluate Front	14	1.0	0.7	9.8	77625	1	1087	110	3.8%
IMAC Eluate	16.6	1.0	4.6	77.2	75941	20	25212	327	89.0%
IMAC Eluate Tail	6.7	1.0	1.4	9.3	40388	5	1353	145	4.8%
IMAC 100mM Imid.	38	1.0	0.4	16.7	29197	1	1109	66	3.9%
									6.8%

Buffers:	Mass Balance Units (from load)	Mass Balance Protein
	104.2%	115.1%
Charge	50 mM NiSO4	
Equilibration	0.02 M Na3PO4, 0.4 M NaCl, 0.002 M Imidazole, 0.01% Triton, pH 7.0	
Wash	0.02 M Na3PO4, 0.4 M NaCl, 0.005 M Imidazole, 0.01% Triton, pH 7.0	
Elution	0.02 M Na3PO4, 0.4 M NaCl, 0.050 M Imidazole, 0.01% Triton, pH 7.0	
Strip	100 mM Imidazole	
Sanitize	1 M NaOH	
Storage	0.001 M NaOH	

**Figure 9**

Standard Curve:

BSA Stock: 2000 ug/mL

Well#	ug/mL BSA	BSA (uL)	Water (uL)
1	0	0	40
2	50	1	39
3	125	2.5	37.5
4	250	5	35
5	500	10	30
6	750	15	25
7	1000	20	20

Samples:

Number of samples Don't include triplicates):	
10	19

For 10uL per standard, run in triplicate

	1	2	3	4	5	6	7	8	9	10	11	12
A	Std 1	Std 1	Std 1	Sample 1	Sample 1	Sample 1	Sample 9	Sample 9	Sample 9	Sample 17	Sample 17	Sample 17
B	Std 2	Std 2	Std 2	Sample 2	Sample 2	Sample 2	Sample 10	Sample 10	Sample 10	Sample 18	Sample 18	Sample 18
C	Std 3	Std 3	Std 3	Sample 3	Sample 3	Sample 3	Sample 11	Sample 11	Sample 11	Sample 19	Sample 19	Sample 19
D	Std 4	Std 4	Std 4	Sample 4	Sample 4	Sample 4	Sample 12	Sample 12	Sample 12	Sample 20	Sample 20	Sample 20
E	Std 5	Std 5	Std 5	Sample 5	Sample 5	Sample 5	Sample 13	Sample 13	Sample 13	Sample 21	Sample 21	Sample 21
F	Std 6	Std 6	Std 6	Sample 6	Sample 6	Sample 6	Sample 14	Sample 14	Sample 14	Sample 22	Sample 22	Sample 22
G	Std 7	Std 7	Std 7	Sample 7	Sample 7	Sample 7	Sample 15	Sample 15	Sample 15	Sample 23	Sample 23	Sample 23
H				Sample 8	Sample 8	Sample 8	Sample 16	Sample 16	Sample 16	Sample 24	Sample 24	Sample 24

1 Remove appropriate amount of reagent and let it come to RT

2 Add 10uL Standard or sample to each well

3 Add 300uL Reagent to each well using multichannel pipettor

4 Incubate at RT 10min

5 Read on VersaMax

Sample #	Dilution	Protein (uL)	Bradford (ug/mL)	Water (uL)	ug/uL
1	CE	100	2	198	15255.9
2	IMAC Load	50	4	196	7629.2
3	IMAC FT	50	4	196	2270.7
4	IMAC Equil Wash	25	8	192	2810.3
5	5AC 5mM Imidazole Wash	10	20	180	559.3
6	IMAC Void	10	20	180	432.3
7	IMAC Eluate Front	10	20	180	702.7
8	IMAC Eluate	50	4	196	4649.2
9	IMAC Eluate Tail	25	8	192	1389
10	IMAC 100mM Imidazole	10	20	180	439.3

**Gel 1**

Lane	Sample	TP Conc. (ug/ul)	Conc. for gel (ug)	Dilution (X)	Sample buffer (ul)	Protein (for 10ug/25uL)	ddH2O (ul)
1	<b>BIORAD Standard</b>	--	--	1		1.00	11.50
2	<b>CE</b>	15.256	10	1		0.66	11.84
3	<b>IMAC Load</b>	7.6292	10	1		1.31	11.19
4	<b>IMAC FT</b>	2.2707	10	1		4.40	8.10
5	<b>IMAC Equil Wash</b>	2.8103	10	1		3.56	8.94
6	<b>IMAC 5mM Imidazole Wash</b>	0.5593	10	1		12.50	0.00

Only 7ug loaded


**15/20**

**Figure 10A**

16/20

**Gel 1:**

Lane	Sample	TP Conc. (ug/uL)	Conc. for gel (ug)	Dilution (X)	Sample buffer (uL)	Protein (for 10ug/25uL)	ddH2O (uL)
1	BIORAD Standard	--	--	1		1.00	11.5
2	IMAC Void	0.4323	10	1		12.50	0.00
3	IMAC Eluate Front	0.7027	10	1	12.5	12.50	0.00
4	IMAC Eluate	4.6492	10	1		2.15	10.35
5	IMAC Eluate Tail	1.389	10	1		7.20	5.3
6	IMAC 100mM Imidazole	0.4393	10	1		12.50	0.00



**Figure 11**

CBS Crude Extract on Chelating Sepharose FF							
Date		Exp. No.		RC-1-39			
Column ID		RC-3-2 Chelating					
Col Vol. =		6.2 mL		Note: column charged to 6.2 mL, 6.5cm			
Total protein/mL resin loaded		14 mg/mL					
Fraction ID	Weight or Volume (g or mL)	CONV.	Protein (mg/mL)	Total Protein in fraction (mg)	Cystathione from assay (nmol.mL.hr)	Dilution factor from assay	Total Units in fraction
CE	11	1.0	8.0	88.0	74067	10	8147
Load	11.4	1.0	8.1	92.3	82223	10	9373
Void	16	1.0	0.3	4.8	7	1	0
FT/Wash	62	1.0	1.2	74.4	5939	1	368
Eluate	25	1.0	2.1	52.5	56851	5	7106
500 mM Imid. Strip	36	1.0	0.2	7.2	1152	1	41
Buffers:				Recovery in Eluate (from load) 75.8%		Mass Balance Units (from CE) 92.3%	
Equilibration	0.02 Phosphate, 0.002 M imidazole, 0.4 M NaCl, pH 7.0			Mass Balance Units (from load) 80.2%		Mass Balance Protein 152.4%	
Wash	0.02 Phosphate, 0.002 M imidazole, 0.4 M NaCl, pH 7.0						
Elution	0.02 Phosphate, 0.1 M imidazole, 0.4 M NaCl, pH 7.0						
Strip	0.5 M Imidazole						
Sanitize	1.0 M NaOH						
Storage	0.001 M NaOH						

18/20

Figure 12

19/20


**Figure 13**

Lane	Sample	TP Conc. (ug/ul)	Conc for gel (ug)	Dilution (X)	Sample buffer (ul)	Protein (for 10ug/25uL)	ddH <sub>2</sub> O (ul)
1	<b>BIORAD Standard</b>	--	--	1		1.00	11.50
2	<b>Equil Wash</b>	11.83	10	1		0.85	11.65
3	<b>5mM Wash</b>	0.2526	10	1	12.5	12.50	0.00
4	<b>8mM Wash</b>	0.6703	10	1		12.50	0.00
5	<b>20mM Wash</b>	0.5249	10	1		12.50	0.00

20/20

# Process Flow Chart

**Figure 14**



Recover approx. 55 grams CBS

Recover approx. 50 grams CBS

11-1635-PCT\_SeqListi ng\_ST25  
SEQUENCE LISTING

<110> The Regents of the University of Colorado  
Carillo, Richard  
Kraus, Jan P.  
Majtan, Thomas  
Naveh, David

<120> PURIFICATION OF CYSTATHIONINE BETA-SYNTHASE

<130> 11-1635-PCT

<140> TBD

<141> 2013-03-25

<150> US 13/830, 494

<151> 2013-03-14

<150> US 61/615, 629

<151> 2012-03-26

<160> 6

<170> PatentIn version 3.5

<210> 1

<211> 1656

<212> DNA

<213> Homo sapiens

<400> 1  
atgccttctg agaccccca ggcagaagtg gggccacag gctgccccca ccgctcaggg 60  
ccacactcgg cgaaggggag cctggagaag gggtccccag aggataagga agccaaggag 120  
ccctgtgga tccggccca tgctccgagc aggtgcacct ggcagctggg ccggcctgcc 180  
tccgagtccc cacatcacca cactgccccg gcaaaatctc caaaaatctt gccagatatt 240  
ctgaagaaaa tcggggacac ccctatggtc agaatcaaca agattggaa gaagttcggc 300  
ctgaagtgtg agctcttggc caagtgtgag ttcttcaacg cgggcgggag cgtgaaggac 360  
cgcatcagcc tgcggatgat tgaggatgct gagcgcgacg ggacgctgaa gcccggggac 420  
acgattatcg agccgacatc cggAACACC gggatcgggc tggccctggc tgcggcagtg 480  
agggctatc gctgcatcat cgtatgcca gagaagatga gctccgagaa ggtggacgtg 540  
ctgcggcac tggggctga gattgtgagg acgcccacca atgccaggtt cgactcccc 600  
gagtcacacg tgggggtggc ctggcgctg aagaacaaa tcccccaattc tcacatccta 660  
gaccagtacc gcaacgcccag caacccctg gctcactacg acaccaccgc tcatgagatc 720  
ctgcagcagt gtatggaa gctggacatg ctggtggtt cagtggcac gggcggcacc 780  
atcacggca ttgccaggaa gctgaaggag aagtgtcctg gatgcaggat cattgggtg 840  
gatcccgaag ggtccatcct cgcaagccg gaggagctga accagacgga gcagacaacc 900  
tacgaggtgg aaggatcg ctacgacttc atccccacgg tgctggacag gacgggtgg 960  
gacaagtgg tcaagagcaa cgatgaggag gcgttccaccc ttgcccccat gctgatcg 1020  
caagaggggc tgctgtgcgg tggcagtgt ggcagcacgg tggcggtgcc cgtgaaggct 1080  
gcgcaggagc tgcaggaggg ccagcgctgc gtggtcattc tggccgactc agtgcggAAC 1140

## 11-1635-PCT\_SeqList string\_ST25

tacatgacca	agttcctgag	cgacaggtgg	atgctgcaga	aggccttct	gaaggaggag	1200
gacctcacgg	agaagaagcc	ctgggtgg	cacccctcg	ttcaggagct	gggcctgtca	1260
gccccgctga	ccgtgctccc	gaccatcacc	tgtgggcaca	ccatcgagat	cctccggag	1320
aaggcctcg	accaggcgcc	cgtggtgat	gaggcggggg	taatcctgg	aatggtgacg	1380
cttggaaaca	tgctctcg	cctgcttgcc	gggaagggtgc	agccgtcaga	ccaagttggc	1440
aaagtcatct	acaagcagtt	caaacagatc	cgcctcacgg	acacgctgg	caggctctcg	1500
cacatcctgg	agatggacca	cttcgcctg	gtggtgacg	agcagatcca	gtaccacagc	1560
accggaaagt	ccagtcagcg	gcagatgg	ttcgggtgg	tcaccgccc	tgacttgctg	1620
aacttcgtgg	ccgcccagga	gcgggaccag	aagtga			1656

&lt;210&gt; 2

&lt;211&gt; 551

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

Met	Pro	Ser	Gl u	Thr	Pro	Gl n	Al a	Gl u	Val	Gl y	Pro	Thr	Gl y	Cys	Pro
1			5						10					15	

Hi s	Arg	Ser	Gl y	Pro	Hi s	Ser	Al a	Lys	Gl y	Ser	Leu	Gl u	Lys	Gl y	Ser
			20					25					30		

Pro	Gl u	Asp	Lys	Gl u	Al a	Lys	Gl u	Pro	Leu	Trp	Ile	Arg	Pro	Asp	Al a
			35				40					45			

Pro	Ser	Arg	Cys	Thr	Trp	Gl n	Leu	Gl y	Arg	Pro	Al a	Ser	Gl u	Ser	Pro
					55					60					

Hi s	Hi s	Hi s	Thr	Al a	Pro	Al a	Lys	Ser	Pro	Lys	Ile	Leu	Pro	Asp	Ile
				65						75				80	

Leu	Lys	Lys	Ile	Gl y	Asp	Thr	Pro	Met	Val	Arg	Ile	Asn	Lys	Ile	Gl y
			85					90					95		

Lys	Lys	Phe	Gl y	Leu	Lys	Cys	Gl u	Leu	Leu	Al a	Lys	Cys	Gl u	Phe	Phe
			100				105					110			

Asn	Al a	Gl y	Gl y	Ser	Val	Lys	Asp	Arg	Ile	Ser	Leu	Arg	Met	Ile	Gl u
					115			120					125		

Asp	Al a	Gl u	Arg	Asp	Gl y	Thr	Leu	Lys	Pro	Gl y	Asp	Thr	Ile	Ile	Gl u
					130			135			140				

Pro	Thr	Ser	Gl y	Asn	Thr	Gl y	Ile	Gl y	Leu	Al a	Leu	Al a	Al a	Al a	Val
					145			150			155			160	

Arg	Gl y	Tyr	Arg	Cys	Ile	Ile	Val	Met	Pro	Gl u	Lys	Met	Ser	Ser	Gl u

165

170

175

Lys Val Asp Val Leu Arg Ala Leu Gly Ala Glu Ile Val Arg Thr Pro  
 180 185 190

Thr Asn Ala Arg Phe Asp Ser Pro Glu Ser His Val Gly Val Ala Trp  
 195 200 205

Arg Leu Lys Asn Glu Ile Pro Asn Ser His Ile Leu Asp Gln Tyr Arg  
 210 215 220

Asn Ala Ser Asn Pro Leu Ala His Tyr Asp Thr Thr Ala Asp Glu Ile  
 225 230 235 240

Leu Gln Gln Cys Asp Gly Lys Leu Asp Met Leu Val Ala Ser Val Gly  
 245 250 255

Thr Gly Gly Thr Ile Thr Gly Ile Ala Arg Lys Leu Lys Glu Lys Cys  
 260 265 270

Pro Gly Cys Arg Ile Ile Gly Val Asp Pro Glu Gly Ser Ile Leu Ala  
 275 280 285

Gl u Pro Gl u Gl u Leu Asn Gl n Thr Gl u Gl n Thr Thr Tyr Gl u Val Gl u  
 290 295 300

Gly Ile Gly Tyr Asp Phe Ile Pro Thr Val Leu Asp Arg Thr Val Val  
 305 310 315 320

Asp Lys Trp Phe Lys Ser Asn Asp Gl u Gl u Ala Phe Thr Phe Ala Arg  
 325 330 335

Met Leu Ile Ala Gl n Gl u Gl y Leu Leu Cys Gl y Gl y Ser Ala Gl y Ser  
 340 345 350

Thr Val Ala Val Ala Val Lys Ala Ala Gl n Gl u Leu Gl n Gl u Gl y Gl n  
 355 360 365

Arg Cys Val Val Ile Leu Pro Asp Ser Val Arg Asn Tyr Met Thr Lys  
 370 375 380

Phe Leu Ser Asp Arg Trp Met Leu Gl n Lys Gl y Phe Leu Lys Gl u Gl u  
 385 390 395 400

Asp Leu Thr Gl u Lys Lys Pro Trp Trp Trp His Leu Arg Val Gl n Gl u  
 405 410 415

Leu Gl y Leu Ser Ala Pro Leu Thr Val Leu Pro Thr Ile Thr Cys Gl y  
 420 425 430

His Thr Ile Gl u Ile Leu Arg Gl u Lys Gl y Phe Asp Gl n Ala Pro Val  
 Page 3

11-1635-PCT\_SeqList string\_ST25  
435 440 445

Val Asp Glu Ala Gly Val Ile Leu Glu Met Val Thr Leu Glu Asn Met  
450 455 460 465

Leu Ser Ser Leu Leu Ala Glu Lys Val Glu Pro Ser Asp Glu Val Glu  
465 470 475 480

Lys Val Ile Tyr Lys Glu Phe Lys Glu Ile Arg Leu Thr Asp Thr Leu  
485 490 495

Gly Arg Leu Ser His Ile Leu Glu Met Asp His Phe Ala Leu Val Val  
500 505 510

His Glu Glu Ile Glu Tyr His Ser Thr Gly Lys Ser Ser Glu Arg Glu  
515 520 525

Met Val Phe Glu Val Val Thr Ala Ile Asp Leu Leu Asn Phe Val Ala  
530 535 540

Ala Glu Glu Arg Asp Glu Lys  
545 550

<210> 3  
<211> 413  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Synthetic

<400> 3

Met Pro Ser Glu Thr Pro Glu Ala Glu Val Glu Pro Thr Glu Cys Pro  
1 5 10 15

His Arg Ser Glu Pro His Ser Ala Lys Glu Ser Leu Glu Lys Glu Ser  
20 25 30

Pro Glu Asp Lys Glu Ala Lys Glu Pro Leu Trp Ile Arg Pro Asp Ala  
35 40 45

Pro Ser Arg Cys Thr Trp Glu Leu Glu Arg Pro Ala Ser Glu Ser Pro  
50 55 60

His His His Thr Ala Pro Ala Lys Ser Pro Lys Ile Leu Pro Asp Ile  
65 70 75 80

Leu Lys Lys Ile Glu Asp Thr Pro Met Val Arg Ile Asn Lys Ile Glu  
85 90 95

Lys Lys Phe Glu Leu Lys Cys Glu Leu Leu Ala Lys Cys Glu Phe Phe  
100 105 110

11-1635-PCT\_SeqList string\_ST25

Asn Ala Gly Gly Ser Val Lys Asp Arg Ile Ser Leu Arg Met Ile Glu  
115 120 125

Asp Ala Glu Arg Asp Gly Thr Leu Lys Pro Gly Asp Thr Ile Ile Glu  
130 135 140

Pro Thr Ser Gly Asn Thr Gly Ile Gly Leu Ala Leu Ala Ala Ala Val  
145 150 155 160

Arg Gly Tyr Arg Cys Ile Ile Val Met Pro Glu Lys Met Ser Ser Glu  
165 170 175

Lys Val Asp Val Leu Arg Ala Leu Gly Ala Glu Ile Val Arg Thr Pro  
180 185 190

Thr Asn Ala Arg Phe Asp Ser Pro Glu Ser His Val Gly Val Ala Trp  
195 200 205

Arg Leu Lys Asn Glu Ile Pro Asn Ser His Ile Leu Asp Gln Tyr Arg  
210 215 220

Asn Ala Ser Asn Pro Leu Ala His Tyr Asp Thr Thr Ala Asp Glu Ile  
225 230 235 240

Leu Gln Gln Cys Asp Gly Lys Leu Asp Met Leu Val Ala Ser Val Gly  
245 250 255

Thr Gly Gly Thr Ile Thr Gly Ile Ala Arg Lys Leu Lys Glu Lys Cys  
260 265 270

Pro Gly Cys Arg Ile Ile Gly Val Asp Pro Glu Gly Ser Ile Leu Ala  
275 280 285

Glu Pro Glu Glu Leu Asn Gln Thr Glu Gln Thr Thr Tyr Glu Val Glu  
290 295 300

Gly Ile Gly Tyr Asp Phe Ile Pro Thr Val Leu Asp Arg Thr Val Val  
305 310 315 320

Asp Lys Trp Phe Lys Ser Asn Asp Glu Glu Ala Phe Thr Phe Ala Arg  
325 330 335

Met Leu Ile Ala Gln Glu Gly Leu Leu Cys Gly Gly Ser Ala Gly Ser  
340 345 350

Thr Val Ala Val Ala Val Lys Ala Ala Gln Glu Leu Gln Glu Gly Gln  
355 360 365

Arg Cys Val Val Ile Leu Pro Asp Ser Val Arg Asn Tyr Met Thr Lys  
370 375 380

11-1635-PCT\_SeqLi sti ng\_ST25

Phe Leu Ser Asp Arg Trp Met Leu Gl n Lys Gl y Phe Leu Lys Gl u Gl u  
385 390 395 400

Asp Leu Thr Gl u Lys Lys Pro Trp Trp Trp His Leu Arg  
405 410

<210> 4

<211> 1242

<212> DNA

<213> Arti fici al Sequence

<220>

<223> Synthetic

<400> 4

atgccgtcag	aaaccccgca	ggcagaagtg	ggtccgacgg	gttgcccgca	ccgttagcggt	60
ccgcattctg	caaaaggcag	tctggaaaaa	ggttcccg	aagataaaga	agccaaagaa	120
ccgctgtgga	ttcgtccgga	cgcaccgtca	cgctgtacct	ggcagctgg	tcgtccggca	180
agcgaatctc	cgcacatcacca	tacggctccg	gcgaaaagtc	cgaaaattct	gccggatatc	240
ctgaagaaaa	tttgtgacac	cccgatggtt	cgtatcaaca	aaatcggcaa	aaaattcggt	300
ctgaaatg	aactgctggc	taaatgtgaa	tttttcaatg	cgggcggttc	cgtgaaagat	360
cgtatctc	ac	tgcatgat	tgaagatg	ct	gaacgcgacg	420
acgattatcg	aaccgac	ttgcaacacg	ggtatcg	tc	gactgg	480
cgtgg	ttt	cattat	cgtatg	ccg	gac	540
ctgcgtg	ctc	tggcg	aaatgt	ccg	act	600
gaatccat	tggtgttgc	atggc	cgt	aaaacgaa	tcc	660
gatcgtat	gtacg	caatcc	ctg	gac	att	720
ctgcagca	gtgatgg	actgg	ctgg	at	tcg	780
attacgg	tcgcgt	actgaa	actg	cc	at	840
gatccg	g	aaatg	ccg	tc	tcg	900
tatgaagt	tt	ttt	ttt	ttt	ttt	960
gacaaat	ttt	ttt	ttt	ttt	ttt	1020
caggaagg	ttt	ttt	ttt	ttt	ttt	1080
g	ttt	ttt	ttt	ttt	ttt	1140
taat	ttt	ttt	ttt	ttt	ttt	1200
catgac	ttt	ttt	ttt	ttt	ttt	1242
ttt	ttt	ttt	ttt	ttt	ttt	

<210> 5

<211> 30

<212> DNA

<213> Arti fici al Sequence

<220>

<223> Synthetic oligonucleotide

11-1635-PCT\_SeqListi ng\_ST25

<400> 5  
cgtagaattc acctttgccc gcatgctgat 30

<210> 6  
<211> 35  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic oligonucleotide

<400> 6  
tacgggtacc tcaacggagg tgccaccacc agggc 35